Dr. Reddy’s Reports Temporary Supply Delay for Semaglutide Due to API Issue

Dr. Reddy’s Laboratories has disclosed a quality issue affecting certain batches of its semaglutide product, which were found to be out of specification due to a problem with the Active Pharmaceutical Ingredient (API). Key Highlights: Supply Impact: The API deviation will result in temporary delays in the commercial supply of the affected semaglutide batches. Safety & Regulatory: Dr. Reddy’s has explicitly confirmed that there is no impact on patient safety, nor are there any adverse effects on the product’s existing global regulatory filings. Corrective Actions: The company has initiated a thorough root-cause investigation and is actively implementing corrective measures to resolve the deviation and restore standard commercial production. Investor Communication: To address stakeholder concerns and provide further operational updates, Dr. Reddy’s management will hold a conference call on July 9, 2026. Strategic Context: While the temporary supply disruption may impact near-term revenue realization for this highly sought-after metabolic therapy, the company's swift transparency and strict adherence to quality protocols reinforce its commitment to patient safety and global regulatory compliance.